AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30615896 — intervention group
Group type: COMPARATOR
Intervention: Observation without glasses unless reduced distance visual acuity, reduced stereoacuity, or manifest strabismus
Number of subjects: 130
Study 28114954 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery in addition to medication
Number of subjects: 238
Study 28114954 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy only
Number of subjects: 238
Study 25790320 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI without fluoroscopy (X‐)
Number of subjects: 80
Study 25790320 — intervention group
Group type: COMPARATOR
Intervention: PVI with fluoroscopy (X+)
Number of subjects: 80
Study 25790320 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (X+ and X‐)
Number of subjects: 80
Study 23003668 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised PDA
Number of subjects: 34
Study 23003668 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (paper-and-pencil aids)
Number of subjects: 34
Study 20732688 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal dexamethasone (DEX)
Number of subjects: 65
Study 20732688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 18443821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dividing attention during viewing of novel naturalistic actions (NNAs)
Number of subjects: 51
Study 18443821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dividing attention during verbal description of NNAs while performing a secondary task
Number of subjects: 51
Study 17915494 — intervention group
Group type: EXPERIMENTAL
Intervention: Language intervention
Number of subjects: 116
Study 17915494 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 116
Study 15476905 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution 0.2%
Number of subjects: 260
Study 15476905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 11778075 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg subcutaneously until Day 13 after PBPCT)
Number of subjects: 71
Study 11778075 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF (5 microg/kg subcutaneously until Day 13 after PBPCT)
Number of subjects: 71
Study 11778075 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 71
Study 11778075 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CD3+ count recovery
Number of subjects: 71
Study 9191824 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectra cell separator
Number of subjects: 15
Study 9191824 — intervention group
Group type: COMPARATOR
Intervention: MCS-3P cell separator
Number of subjects: 15
Study 9191824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both machines
Number of subjects: 15
Study 8466741 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 10
Study 8466741 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 10
Study 3731895 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for COAD patients
Number of subjects: 0
Study 3731895 — intervention group
Group type: COMPARATOR
Intervention: Advised of findings only (Control)
Number of subjects: 0
Study 31658265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile males produced from combining the sterile insect technique using radiation with the insect incompatible technique through Wolbachia‐induced incompatibility (SIT/IIT); approximately 100-200 sterile males released weekly in each household for 6 months.
Number of subjects: 0
Study 31658265 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified); no intervention mentioned.
Number of subjects: 0
Study 29397189 — intervention group
Group type: EXPERIMENTAL
Intervention: 342 μg IBI‐10090 dexamethasone drug delivery suspension
Number of subjects: 394
Study 29397189 — intervention group
Group type: EXPERIMENTAL
Intervention: 517 μg IBI‐10090 dexamethasone drug delivery suspension
Number of subjects: 394
Study 29397189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 26597138 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal instruction to down-regulate emotional arousal
Number of subjects: 0
Study 26597138 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related potentials (ERPs)
Number of subjects: 0
Study 26597138 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral responses
Number of subjects: 0
Study 24918735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured epithelial autografts (JACE) combined with autograft and artificial dermis preparation
Number of subjects: 39
Study 24918735 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 39
Study 22149003 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg/day)
Number of subjects: 24
Study 22149003 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan (40 mg/day)
Number of subjects: 24
Study 19513973 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (180 mg/day)
Number of subjects: 137
Study 19513973 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (150 mg/day)
Number of subjects: 137
Study 17489767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytics (administered within six hours of first chest symptoms)
Number of subjects: 0
Study 17489767 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulants (administered after optimal time)
Number of subjects: 0
Study 15195762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic 123I-MIBG SPECT
Number of subjects: 76
Study 14508326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 36
Study 14508326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 36
Study 14508326 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 36
Study 10576122 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2) treatment
Number of subjects: 8
Study 10576122 — intervention group
Group type: COMPARATOR
Intervention: Healthy donors
Number of subjects: 8
Study 8896528 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccines
Number of subjects: 2342
Study 8896528 — intervention group
Group type: COMPARATOR
Intervention: Control whole cell vaccine
Number of subjects: 2342
Study 1665490 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion chemotherapy with doxorubicin and ifosfamide
Number of subjects: 159
Study 1665490 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus chemotherapy with doxorubicin and ifosfamide
Number of subjects: 159
Study 6342842 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol 320 mg once daily
Number of subjects: 1456
Study 6342842 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1456
Study 3083467 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change programming delivered by church volunteers on major cardiovascular risk factors (smoking, elevated blood pressure, elevated serum cholesterol, excess weight, and physical inactivity).
Number of subjects: 20
Study 3083467 — intervention group
Group type: EXPERIMENTAL
Intervention: Training special task forces to coordinate efforts within each church.
Number of subjects: 20
Study 3083467 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of professional (paid staff) involvement.
Number of subjects: 20
Study 3083467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of professional (paid staff) involvement.
Number of subjects: 20
Study 3083467 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental conditions testing the necessity of training special task forces.
Number of subjects: 20
Study 29739738 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time counseling via text-chat
Number of subjects: 534
Study 29739738 — intervention group
Group type: COMPARATOR
Intervention: No real-time counseling via text-chat
Number of subjects: 534
Study 29739738 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 days intervention duration
Number of subjects: 534
Study 29739738 — intervention group
Group type: COMPARATOR
Intervention: 28 days intervention duration
Number of subjects: 534
Study 29739738 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (regardless of intervention)
Number of subjects: 534
Study 28159671 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic checklist intervention
Number of subjects: 6207
Study 25771030 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cooling (CCP applied to neck, groin, and axillae)
Number of subjects: 10
Study 25771030 — intervention group
Group type: EXPERIMENTAL
Intervention: Glabrous skin cooling (CCP applied to cheeks, palms, and soles)
Number of subjects: 10
Study 25771030 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 10
Study 23936981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate 200 mg/day
Number of subjects: 96
Study 23936981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate 200 mg/day + Ascorbic acid 100 mg/day
Number of subjects: 96
Study 23936981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate 200 mg/day + Ascorbic acid 500 mg/day
Number of subjects: 96
Study 19959335 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (10 cc of 2.5mg/cc with 1:80.000 epinephrine)
Number of subjects: 200
Study 19959335 — intervention group
Group type: COMPARATOR
Intervention: Control (no bupivacaine)
Number of subjects: 200
Study 18260764 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of vaccine per dose with MF59
Number of subjects: 394
Study 18260764 — intervention group
Group type: COMPARATOR
Intervention: 45 microg per dose of vaccine alone
Number of subjects: 394
Study 18260764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine at 15 or 7.5 microg per dose with MF59
Number of subjects: 394
Study 18260764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine at 30, 15, or 7.5 microg per dose with aluminum hydroxide
Number of subjects: 394
Study 16809802 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxsalen (40 mg)
Number of subjects: 12
Study 16809802 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (200 mg)
Number of subjects: 12
Study 14570793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Compression Device (SCD) with thigh-high sleeves at a preset pressure of 50 mm Hg
Number of subjects: 50
Study 14570793 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SCD)
Number of subjects: 50
Study 11094856 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-B (poori and dal-fry)
Number of subjects: 8
Study 11094856 — intervention group
Group type: COMPARATOR
Intervention: Diet-A (idly with chutney)
Number of subjects: 8
Study 8627582 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg tirilazad mesylate solution orally with 200 mg ketoconazole once daily
Number of subjects: 12
Study 8627582 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg i.v. tirilazad mesylate solution with 200 mg ketoconazole once daily
Number of subjects: 12
Study 8627582 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/kg tirilazad mesylate solution orally
Number of subjects: 12
Study 8627582 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg i.v. tirilazad mesylate solution
Number of subjects: 12
Study 8627582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 12
Study 1360277 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of azidothymidine (AZT), group A
Number of subjects: 28
Study 1360277 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day of azidothymidine (AZT), group B
Number of subjects: 28
Study 3881645 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble insulin at 10 U/mL
Number of subjects: 8
Study 3881645 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble insulin at 40 U/mL
Number of subjects: 8
Study 3881645 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble insulin at 100 U/mL
Number of subjects: 8
Study 3881645 — intervention group
Group type: COMPARATOR
Intervention: Bolus SC injection of soluble insulin at 40 U/mL
Number of subjects: 8
Study 30211719 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystem balance training (8 weeks)
Number of subjects: 84
Study 30211719 — intervention group
Group type: COMPARATOR
Intervention: Upper limbs group (control)
Number of subjects: 84
Study 29232180 — intervention group
Group type: EXPERIMENTAL
Intervention: ParentNet app
Number of subjects: 161
Study 26616678 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (3-week course)
Number of subjects: 31
Study 25121991 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 581
Study 25121991 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 581
Study 21928921 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback indicating progress on egalitarian goals
Number of subjects: 0
Study 21928921 — intervention group
Group type: COMPARATOR
Intervention: Feedback indicating failure on egalitarian goals
Number of subjects: 0
Study 21928921 — intervention group
Group type: COMPARATOR
Intervention: No feedback on egalitarian goals
Number of subjects: 0
Study 20483887 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter dose botulinum toxin A
Number of subjects: 30
Study 20483887 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose botulinum toxin A
Number of subjects: 30
Study 20483887 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injections (Control)
Number of subjects: 30
Study 17512550 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min clamp/5-min release regime (group 1)
Number of subjects: 13
Study 17512550 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-min clamp/10-min release regime (group 2)
Number of subjects: 13
Study 17512550 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 13
Study 15459914 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thyroidectomy (VAT)
Number of subjects: 20
Study 15459914 — intervention group
Group type: COMPARATOR
Intervention: Conventional thyroidectomy
Number of subjects: 20
Study 11896514 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rEpo)
Number of subjects: 357
Study 11896514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 10214018 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin E1 (PGE1) 8 micrograms.g‐1
Number of subjects: 4
Study 10214018 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin E1 (PGE1) 4 micrograms.g‐1
Number of subjects: 4
Study 10214018 — intervention group
Group type: COMPARATOR
Intervention: Topical prostaglandin E1 (PGE1) 0 microgram.g‐1, 2 micrograms.g‐1, 4 micrograms.g‐1, and 8 micrograms.g‐1
Number of subjects: 4
Study 8535682 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 69
Study 8535682 — intervention group
Group type: COMPARATOR
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 69
Study 2712654 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-strength (diluted group) milk
Number of subjects: 69
Study 2712654 — intervention group
Group type: COMPARATOR
Intervention: Full strength (undiluted group) milk
Number of subjects: 69
Study 709214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of labetalol
Number of subjects: 17
Study 709214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of labetalol
Number of subjects: 17
Study 31527093 — intervention group
Group type: EXPERIMENTAL
Intervention: CLACfast (≤2 FiO2 adjustments/min)
Number of subjects: 19
Study 31527093 — intervention group
Group type: COMPARATOR
Intervention: CLACslow (≤0.3 FiO2 adjustments/min)
Number of subjects: 19
Study 31527093 — intervention group
Group type: COMPARATOR
Intervention: RMConly (routine manual control)
Number of subjects: 19
Study 30346317 — intervention group
Group type: EXPERIMENTAL
Intervention: Defecation Postural Modification Device (DPMD)
Number of subjects: 52
Study 30346317 — intervention group
Group type: COMPARATOR
Intervention: No DPMD
Number of subjects: 52
Study 29424804 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/d)
Number of subjects: 63
Study 29424804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 25957010 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic interval training (AIT)
Number of subjects: 33
Study 25957010 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised continuous moderate exercise training (CMT)
Number of subjects: 33
Study 25957010 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised control group (CON)
Number of subjects: 33
Study 24638852 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher nicotine cigarettes
Number of subjects: 120
Study 24638852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower nicotine cigarettes
Number of subjects: 120
Study 24638852 — intervention group
Group type: EXPERIMENTAL
Intervention: All test cigarettes
Number of subjects: 120
Study 22937145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 21
Study 22937145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 19545338 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducibility of ventricular arrhythmias (VT or VF)
Number of subjects: 204
Study 19545338 — intervention group
Group type: COMPARATOR
Intervention: Non-inducibility of ventricular arrhythmias
Number of subjects: 204
Study 17309377 — intervention group
Group type: EXPERIMENTAL
Intervention: FSN intervention (needles inserted and swayed in the subcutaneous layer 200 times in 2 minutes)
Number of subjects: 47
Study 15036490 — intervention group
Group type: EXPERIMENTAL
Intervention: peroral estradiol valerate 2 mg/day
Number of subjects: 58
Study 15036490 — intervention group
Group type: EXPERIMENTAL
Intervention: transdermal estradiol gel containing 1 mg estradiol/day
Number of subjects: 58
Study 11804247 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihydroxyethylrutosides (HR) 300 mg, 2 tablets daily for 2 weeks
Number of subjects: 53
Study 11804247 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihydroxyethylrutosides (HR) 300 mg, continued for another 2 weeks if symptoms persisted
Number of subjects: 53
Study 11804247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 9893776 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 250
Study 9893776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 8164116 — intervention group
Group type: COMPARATOR
Intervention: Water irrigation (Group B)
Number of subjects: 155
Study 8164116 — intervention group
Group type: COMPARATOR
Intervention: Zinc sulfate irrigation (Group C)
Number of subjects: 155
Study 2820619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic combination of 2 mg oestradiol valerate (21 d) and 1 mg cyproterone acetate (11 d)
Number of subjects: 76
Study 2820619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 29540584 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 5 mg/kg/d
Number of subjects: 34
Study 29540584 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 10 mg/kg/d
Number of subjects: 34
Study 29540584 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 20 mg/kg/d
Number of subjects: 34
Study 29540584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 26750743 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based self-management support intervention delivered by lay health educators
Number of subjects: 443
Study 25280823 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT), 8 sessions
Number of subjects: 61
Study 25280823 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (E-TAU)
Number of subjects: 61
Study 22035956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling during 10 contacts
Number of subjects: 66
Study 22035956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements as needed until three months after hip fracture surgery
Number of subjects: 66
Study 20142336 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-injection technique (group 1, n = 56)
Number of subjects: 120
Study 20142336 — intervention group
Group type: COMPARATOR
Intervention: 4-injection technique (group 2, n = 58)
Number of subjects: 120
Study 17432681 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) plus standard CHF treatment (angiotensin converting enzyme inhibitor, beta‐receptor inhibitor, digoxin, diuretic) for six months
Number of subjects: 68
Study 17432681 — intervention group
Group type: COMPARATOR
Intervention: Standard CHF treatment (angiotensin converting enzyme inhibitor, beta‐receptor inhibitor, digoxin, diuretic)
Number of subjects: 68
Study 16234567 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 188
Study 16234567 — intervention group
Group type: EXPERIMENTAL
Intervention: PIAF (Cisplatin, interferon alpha-2b, doxorubicin, fluorouracil)
Number of subjects: 188
Study 11864671 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg oral misoprostol
Number of subjects: 42
Study 11864671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7743295 — intervention group
Group type: EXPERIMENTAL
Intervention: Curosurf (200 mg/kg initial dose; up to two additional doses of 100 mg/kg after 12 and 24 hours if needed)
Number of subjects: 75
Study 7743295 — intervention group
Group type: COMPARATOR
Intervention: Survanta (100 mg/kg initial dose; up to three additional doses of 100 mg/kg between six and 48 hours if needed)
Number of subjects: 75
Study 2195163 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 2195163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 352191 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% etidocaine
Number of subjects: 41
Study 352191 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 41
Study 29804498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoffending mother scenario
Number of subjects: 154
Study 29804498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoffending father scenario
Number of subjects: 154